The agency said April 30 that Battelle requested that the authorization be revoked.
“In response to changing customer needs, as of March 31, 2021, Battelle has ceased all Battelle CCDS decontamination site operations and marketing activities,” the FDA wrote.
The FDA recently urged hospitals to move away from using crisis capacity conservation strategies such as decontamination to extend the use of N95 and other masks, citing an increased domestic supply.
The FDA granted authorization to Battelle’s mask decontamination system in March 2020. The company received more than $400 million in federal contracts to develop the system, which can sterilize 10,000 masks in 150 minutes.
The agency sent a warning letter to Battelle in October, saying it didn’t have adequate procedures for identifying adverse events. The National Nurses Union had alleged the technology was “not safe and may not work.”
Dozens of nurses reported last May that they had negative reactions to the decontaminated masks, including sore throats, headaches and nausea.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.